Document Detail

The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial.
MedLine Citation:
PMID:  17598009     Owner:  NLM     Status:  MEDLINE    
Low-molecular-weight heparin (LMWH) is increasingly being used for prophylaxis of venous thromboembolism (VTE) and prevention of pregnancy associated morbidity in pregnant women with thrombophilia. We sought to determine if the administration of prophylactic doses of LMWH downregulates coagulation activation in high risk pregnant women with thrombophilia. This sub-study was planned as part of a randomized open label controlled trial (Thrombophilia in Pregnancy Prophylaxis Study [TIPPS]) in which patients at high risk of pregnancy complications with confirmed thrombophilia are randomized to receive either dalteparin (5,000 units/day until 20 weeks then 5,000 units q12h until 37 weeks or onset of labor) or no treatment. Blood samples were collected at baseline, day 7-9 (after starting study drug), week 20 (before increasing study drug), week 36 (prior to stopping study drug) and at the time of admission to the labor and delivery unit. Samples were not drawn at fixed times in relation to drug injection. These samples were analyzed for levels of thrombin-antithrombin complexes (TAT), prothrombin fragments 1 + 2 (F1.2), D-dimer and anti-Xa activity. Generalized linear mixed models were used for statistical analysis and model results were controlled for age, smoking status, type of thrombophilia and predisposing risk factors. The effect of dalteparin on TAT levels was defined as the primary outcome. Of 198 patients eligible, 114 were enrolled in TIPPS. Ninety-one were eligible for the TIPPS coagulation activation sub-study and randomized. Thirty-nine patients were analyzed in the treatment group (dalteparin) and 46 patients in the control group (no intervention). Levels of coagulation activation factors F1.2, TAT and D-dimer increased significantly throughout pregnancy in both groups (p < 0.0001). Dalteparin prophylaxis resulted in a significant increase in anti-Xa activity through pregnancy (p < 0.0001) compared to controls. Dalteparin had no significant effects on the levels of TAT, F1.2 and D-dimer throughout pregnancy in thrombophilic women. A post-hoc Monte Carlo power analysis revealed that our study had 100% and 88% power to detect reductions in TAT values on treatment of 50% and 25%, respectively. Prophylaxis with dalteparin at doses used in this study did not reduce coagulation activation in high risk thrombophilic women during pregnancy.
Karim Abou-Nassar; Michael J Kovacs; Susan R Kahn; Philip Wells; Steve Doucette; Tim Ramsay; Anne Marie Clement; Rshmi Khurana; Karen Mackinnon; Mark Blostein; Susan Solymoss; John Kingdom; Matthew Sermer; Evelyne Rey; Marc Rodger;
Related Documents :
12860349 - Bilateral internal jugular venous thrombosis following successful assisted conception i...
17251669 - Risks and pregnancy outcome in women with prosthetic mechanical heart valve replacement.
1545269 - Spontaneous intracerebral hematoma from occult carotid-cavernous fistula during pregnan...
21843969 - Reducing multiple pregnancies after assisted reproduction treatment: québec says 'yes, ...
22039029 - Perinatal outcomes in twin pregnancies with discordant doppler velocimetric findings.
2340259 - Late symptoms after pregnancy-related deep vein thrombosis.
1909979 - Intramural-isthmic fallopian tube anastomosis facilitated by the carbon dioxide laser.
12832369 - Pregnancy outcome in women with pcos and in controls matched by age and weight.
22511519 - Pharmacologic treatment of hyperthyroidism during pregnancy.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  98     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  2007 Jul 
Date Detail:
Created Date:  2007-06-28     Completed Date:  2007-09-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  163-71     Citation Subset:  IM    
The Ottawa Hospital, General Campus, 501 Smyth Road, Box 201, Ottawa, ONT K1H 8L6, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticoagulants / administration & dosage
Antithrombin III
Biological Markers / blood
Blood Coagulation / drug effects*
Dalteparin / administration & dosage*
Heparin, Low-Molecular-Weight
Peptide Hydrolases / blood
Pregnancy Complications, Hematologic / drug therapy
Risk Factors
Thrombophilia / complications,  drug therapy*
Reg. No./Substance:
0/Anticoagulants; 0/Biological Markers; 0/Dalteparin; 0/Heparin, Low-Molecular-Weight; 0/antithrombin III-protease complex; 9000-94-6/Antithrombin III; EC 3.4.-/Peptide Hydrolases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and ...
Next Document:  Intraoperative fresh-frozen plasma versus human albumin in craniofacial surgery--a pilot study compa...